The goal of this clinical trial is to learn if the intraoperative use of a computer guidance software can improve the success of liver tumor ablation in adults. The employed software calculates and displays a simulation of the ablation such that the physician can visualize what portion of the target tumor has, and has not been treated at any point during the procedure. The main questions it aims to answer are: 1) Does the use of the computer guidance software reduce the number of times a tumor is incompletely treated. 2) Does the use of the computer guidance software reduce the rate of local tumor recurrence at 2 year follow-up? 3) Was there an increase or a decrease in medical problems for participants after a procedure where the guidance software was used?
Researchers will compare liver tumor treatment using the computer guidance software with an historic control to see if the addition of the guidance software improved the outcomes after an ablation.
Participants will:
Undergo CT-guided microwave ablation treatment of a liver tumor using computer-assisted simulation. Visit the clinic at one month and then every 3 months for blood tests and a contrast-enhanced CT or MRI imaging study (as per standard of care)
Who can participate
Age range18 Years – 90 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age ≥ 18 years, with life expectancy of at least 1 year
✓. Diagnosis of hepatocellular carcinoma (HCC) confirmed by:
✓. Localized disease without macrovascular invasion or extrahepatic metastasis, eligible for curative-intent percutaneous thermal ablation, defined as:
✓. Tumor location deemed technically feasible for percutaneous ablation by the treating interventional radiologist
✓. ECOG Performance Status 0-2
✓. Adequate coagulation status, defined as:
✓. Ability to undergo contrast-enhanced CT or MRI
✓. Willingness and ability to provide informed consent
Exclusion criteria
✕. Prior local therapy to the target lesion (ablation, TACE, SBRT, or resection) or to a lesion within 1 cm of the target lesion
✕
What they're measuring
1
Local Tumor Progression
Timeframe: Assessed at each imaging follow-up visit ( at every 3 months, up to 24 months).